Table 1.
Clinical and tumor characteristics in the overall population and in the C and CV subgroups.
| Characteristic | Overall | C Subgroup | CV Subgroup | p |
|---|---|---|---|---|
| n = 290 | n = 127 | n = 163 | ||
| Age, Years | <0.001 | |||
| ≥65 | 134 (46.2) | 85 (66.9) | 49 (30.1) | |
| <65 | 156 (53.8) | 42 (33.1) | 114 (69.9) | |
| ECOG PS | ||||
| 0–1 | 281 (96.9) | 120 (94.5) | 161 (98.8) | |
| ≥2 | 9 (3.1) | 7 (5.5) | 2 (1.2) | 0.08 |
| Tumor Biology | ||||
| HR+ | 230 (79.3) | 101 (79.5) | 129 (79.1) | |
| TNBC | 60 (20.7) | 26 (20.5) | 34 (20.9) | 1.00 |
| Line of ChT for mBC | ||||
| 1 | 137 (47.2) | 61 (48.0) | 76 (46.6) | |
| >1 | 153 (52.8) | 66 (52.0) | 87 (53.4) | 0.91 |
| N. of metastatic sites | ||||
| 1 | 80 (27.6) | 38 (29.9) | 42 (25.8) | |
| >1 | 210 (72.4) | 89 (70.1) | 121 (74.2) | 0.51 |
| Visceral disease | ||||
| Yes | 192 (66.2) | 83 (65.4) | 109 (66.9) | |
| No | 98 (33.8) | 44 (34.6) | 54 (33.1) | 0.88 |
| Time to Metastases | ||||
| Synchronous | 44 (15.2) | 19 (15.0) | 25 (15.3) | |
| Metachronous | 246 (84.8) | 108 (85.0) | 138 (84.7) | 1.00 |
|
Previous Anthracycline
Treatment |
||||
| Yes | 228 (78.6) | 88 (69.3) | 140 (85.9) | |
| No | 62 (21.4) | 39 (30.7) | 23 (14.1) | 0.001 |
| Previous Taxane Treatment | ||||
| Yes | 227 (78.2) | 88 (69.3) | 139 (85.3) | |
| No | 63 (21.8) | 39 (30.7) | 24 (14.7) | 0.002 |
| Maintenance Treatment | ||||
| Yes | 47 (16.2) | 18 (14.2) | 29 (17.8) | |
| No | 243 (83.8) | 109 (85.8) | 134 (82.2) | 0.50 |
| C/V in subsequent lines | ||||
| Yes | 83 (28.6) | 42 (33.1) | 41 (25.2) | |
| No | 207 (71.4) | 85 (66.9) | 122 (74.8) | 0.18 |
Data are presented as n (%) except where otherwise noted. The p value of the χ2 test assessing the association between each characteristic and the type of treatment received is indicated in the right column of the table. The p value of the test is indicated in bold numbers when statistically significant. Abbreviations: C: capecitabine; CV: capecitabine-vinorelbine combination; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HR+ BC: hormone receptor-positive breast cancer; TNBC: triple-negative breast cancer. Bold: statistically significant difference.